CG Oncology (CGON) Projected to Announce Earnings on Friday

CG Oncology (NASDAQ:CGON) is expected to release its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of ($0.6642) per share and revenue of $0.3610 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million. On average, analysts expect CG Oncology to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

CG Oncology Stock Up 1.4%

Shares of NASDAQ:CGON opened at $72.42 on Thursday. CG Oncology has a 52 week low of $23.65 and a 52 week high of $77.00. The company has a 50-day moving average price of $66.58 and a 200 day moving average price of $63.73. The company has a market cap of $6.39 billion, a P/E ratio of -31.08 and a beta of 0.23.

Wall Street Analyst Weigh In

CGON has been the subject of a number of analyst reports. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. JPMorgan Chase & Co. lifted their price target on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wolfe Research assumed coverage on CG Oncology in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada increased their price objective on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Insiders Place Their Bets

In other CG Oncology news, Director James Mulay sold 24,165 shares of CG Oncology stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the completion of the transaction, the director owned 24,165 shares in the company, valued at approximately $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the completion of the sale, the director directly owned 5,000 shares in the company, valued at $350,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 37,129 shares of company stock worth $2,663,817. Insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Picton Mahoney Asset Management purchased a new stake in shares of CG Oncology in the fourth quarter valued at $118,000. Tower Research Capital LLC TRC lifted its holdings in CG Oncology by 159.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after purchasing an additional 4,288 shares in the last quarter. Sei Investments Co. acquired a new stake in shares of CG Oncology during the 2nd quarter worth about $209,000. Verition Fund Management LLC acquired a new stake in shares of CG Oncology during the 3rd quarter worth about $221,000. Finally, Man Group plc acquired a new stake in shares of CG Oncology during the 2nd quarter worth about $224,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.